CellforCure

Executive Summary

CELLforCURE by SEQENS is a France-based, EMA-authorized CDMO specializing in cell and gene therapies. With an integrated facility near Paris featuring multiple independent production lines, it provides end-to-end GMP manufacturing from Phase I to commercial scale for autologous and allogeneic ATMPs. Founded in 2001, the company leverages its regulatory expertise and capacity to serve a growing pipeline of advanced therapies. As the cell and gene therapy market expands, CELLforCURE is positioned to capture demand for outsourced manufacturing, particularly in Europe. Its private ownership under SEQENS provides financial stability, though detailed financials are undisclosed.

Upcoming Catalysts (preview)

• Q4 2026Capacity expansion announcement to meet rising ATMP demand70% success
• Q1 2027New multi-year manufacturing contract with a leading gene therapy developer60% success
• Q2 2027Regulatory approval milestone for a client's therapy manufactured at CELLforCURE50% success